Exhibit 107.1
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Damora Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
|
|
|
|
|
|
|
|
|
|
|
Security |
Security Class Title |
Fee Calculation Rule |
Amount Registered |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee |
1 |
Equity |
Common Stock, $0.00001 par value per share |
Rule 457(a) |
9,299,832 |
$20.01 |
$186,089,638.32 |
0.0001381 |
$25,698.98 |
2 |
Equity |
Common Stock, $0.00001 par value per share |
Rule 457(a) |
619,989 |
$20.01 |
$12,405,979.89 |
0.0001381 |
$1,713.27 |
3 |
Equity |
Common Stock, $0.00001 par value per share |
Rule 457(a) |
434,508 |
$7.19 |
$3,124,112.52 |
0.0001381 |
$431.44 |
|
Total Offering Amounts |
|
$201,619,730.73 |
|
$27,843.68 |
|
Total Fee Offsets |
|
|
|
— |
|
Net Fee Due |
|
|
|
$27,843.68 |
1.Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 (this “Registration Statement”) shall also cover any additional shares of Common Stock, $0.00001 par value per share (the “Common Stock”) of Damora Therapeutics, Inc. (the “Registrant”) as may become issuable under the 2026 Damora Therapeutics, Inc. Equity Incentive Plan (the “2026 Plan”) to prevent dilution in the event of stock splits, stock dividends or similar transactions pursuant to the terms of the applicable plans. The proposed maximum offering prices per unit have been estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act based on the average of the high and low sale prices of the Common Stock, as quoted on the Nasdaq Capital Market, on March 19, 2026g
2.Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional shares of Common Stock as may become issuable under the 2026 Damora Therapeutics, Inc. Employee Stock Purchase Plan (the “ESPP”) to prevent dilution in the event of stock splits, stock dividends or similar transactions pursuant to the terms of the applicable plans. The proposed maximum offering prices per unit have been estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act based on the average of the high and low sale prices of the Common Stock, as quoted on the Nasdaq Capital Market, on March 19, 2026.
3.Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional shares of Common Stock as may become issuable under the outstanding options under the Damora Therapeutics, Inc. 2025 Equity Incentive Plan (the “Assumed Options”), which were assumed by the Registrant and converted into stock options to purchase shares of Common Stock, to prevent dilution in the event of stock splits, stock dividends or similar transactions pursuant to the terms of the applicable plans. The proposed maximum offering prices per unit have been estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act based on the weighted average exercise price of the Assumed Options.